{"id":"8a0ad465-6453-5d98-9119-ed421c903190","stable_key":"8b3cf083-ea9c-54f5-b42b-bf1fef5b2978:metformin-human-muscle-ampk","predicate":"increases","statement":"Ten weeks of metformin significantly increased skeletal-muscle AMPK alpha2 activity with increased Thr172 phosphorylation and decreased acetyl-CoA carboxylase-2 activity in people with type 2 diabetes.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"8556fd30-2527-54d2-985d-6cc4997c0ce4","mechanism_event_label":"At the dose people take, the energy sensor is measurably more active in human muscle.","subject":{"id":"519971b1-5aef-5ad7-8022-840144855cd0","slug":"metformin","display_name":"Metformin","entity_type_key":"drug"},"object":{"id":"59b7c30f-59d4-5eab-b5b0-1d0cc330d200","slug":"skeletal-muscle-ampk-activity","display_name":"Skeletal-muscle AMPK activity","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"8556fd30-2527-54d2-985d-6cc4997c0ce4","stable_key":"8b3cf083-ea9c-54f5-b42b-bf1fef5b2978:metformin-human-muscle-ampk-event","event_type":"observed_intervention","label":"At the dose people take, the energy sensor is measurably more active in human muscle.","description":"Ten weeks of metformin significantly increased skeletal-muscle AMPK alpha2 activity with increased Thr172 phosphorylation and decreased acetyl-CoA carboxylase-2 activity in people with type 2 diabetes.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"c9808f71-628e-52db-989a-53f6f128e78c","slug":"acacb","display_name":"Human acetyl-CoA carboxylase 2 / ACACB","entity_type_key":"protein"},"role":"downstream_target","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"95bc303f-ad04-59ea-8e1e-32f9e8b72c56","slug":"human-ampk-complexes","display_name":"Human AMP-activated protein kinase complexes","entity_type_key":"protein_family"},"role":"activated_sensor","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"519971b1-5aef-5ad7-8022-840144855cd0","slug":"metformin","display_name":"Metformin","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"59b7c30f-59d4-5eab-b5b0-1d0cc330d200","slug":"skeletal-muscle-ampk-activity","display_name":"Skeletal-muscle AMPK activity","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/metformin-research/12086935.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"a7807ae8af1c0f438eeff1dd4106d0198681e72f0333f0556786b9151b0df680\", \"start_char\": 0, \"end_char\": 1474, \"text_sha256\": \"a7807ae8af1c0f438eeff1dd4106d0198681e72f0333f0556786b9151b0df680\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Ten weeks of metformin in people with type 2 diabetes with muscle biopsies","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Therapeutic metformin doses for 10 weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A human tissue measurement at therapeutic dose. It is an association within a treatment study, not a demonstration that AMPK causes the glucose disposal change.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake.","comparator":null,"unit":null,"notes":"","entity":{"slug":"metformin","display_name":"Metformin","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"At the dose people take, the energy sensor is measurably more active in human muscle.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[metformin-p12086935] Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. (2002). https://pubmed.ncbi.nlm.nih.gov/12086935/ DOI: 10.2337/diabetes.51.7.2074","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Skeletal muscle","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"8df1e640-747c-5532-9ca3-31fd594119ef","evidence_kind":"source_excerpt","locator":"Lines 736-747","start_line":736,"end_line":747,"excerpt":"### metformin-human-muscle-ampk\nTen weeks of metformin significantly increased skeletal-muscle AMPK alpha2 activity with increased Thr172 phosphorylation and decreased acetyl-CoA carboxylase-2 activity in people with type 2 diabetes.\nCondition category: normal\nnutrient_topic: Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake.\nplain_language: At the dose people take, the energy sensor is measurably more active in human muscle.\norganism: Human\ntissue_or_cell_type: Skeletal muscle\nexperimental_model: Ten weeks of metformin in people with type 2 diabetes with muscle biopsies\nlimitations: A human tissue measurement at therapeutic dose. It is an association within a treatment study, not a demonstration that AMPK causes the glucose disposal change.\nexposure: Therapeutic metformin doses for 10 weeks\nevidence_span: {\"source_cache\": \"artifacts/metformin-research/12086935.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"a7807ae8af1c0f438eeff1dd4106d0198681e72f0333f0556786b9151b0df680\", \"start_char\": 0, \"end_char\": 1474, \"text_sha256\": \"a7807ae8af1c0f438eeff1dd4106d0198681e72f0333f0556786b9151b0df680\"}\n[metformin-p12086935] Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. (2002). https://pubmed.ncbi.nlm.nih.gov/12086935/ DOI: 10.2337/diabetes.51.7.2074","model_system":"Ten weeks of metformin in people with type 2 diabetes with muscle biopsies","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [metformin-p12086935] Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. (2002). https://pubmed.ncbi.nlm.nih.gov/12086935/ DOI: 10.2337/diabetes.51.7.2074","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"d0474bd9-7cfd-5695-a152-12f3633a6813","stable_key":"import-8b3cf083-ea9c-54f5-b42b-bf1fef5b2978","title":"Metformin: transport, molecular targets, gut mechanisms and nutrient interactions (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"0b51d0759aeeb88ac5b3a6277245a196b2bb024d7c32ec89379ed428fb06bfb5","revision_id":"0405c75e-f06e-5af7-a642-1777802f6004","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}